Effects and safety of pregabalin for the treatment of diabetic peripheral neuropathic pain: meta-analysis of randomized controlled trials / 中国药学杂志

ABSTRACT

OBJECTIVE: To compare the effects and safety of pregabalin for the treatment of diabetic peripheral neuropathic pain. METHODS: Cochrane library, MEDLINE, Embase, PUBMED, CNKI, VIP database, Wan fang database and paper manual of related conferences were searched. The Meta-analysis was performed by RevMan 5. 1. RESULTS: Eight studies were included (n = 1596). The analysis indicated that there were significant differences between pregabalin and placebo in respondent rate[OR = 2.81, 95%CI(2.03, 3.89), P < 0.00001], endpoint mean pain scores [WMD = - 1.08, 95% CI(- 1.52, - 0.63), P < 0.00001], patient global impression of change[OR = 2.94, 95% CI(2.05, 4.20), P < 0.00001] and clinical global impression of change[OR = 2.42, 95%CI(1.53, 3.82), P = 0.0001]. The subgroup analysis showed that the efficacy treated with 600 mg·d-1 is superior to that with 300 mg·d-1. The adverse event rate is higher treated with pregabalin than that with placebo [OR = 5.71, 95%CI(4.05, 6.60), P < 0.00001]. Compared with 5% lidocaine(Lignocaine) medicated plaster, the efficacy of pregabalin is similar while adverse event rate is higher. There were similar efficacy and safety between pregabalin and duloxetine. CONCLUSION: With superior effects, similar safety, pregabalin may be preferred for the patients with diabetic peripheral neuropathic pain.